VIDEO: Patients need ‘fair and equitable access’ to TearCare

CHICAGO — In this Healio Video Perspective from the AAO meeting, Neel R. Desai, MD, of The Eye Institute of West Florida discusses the positive impact of the TearCare system on ocular surface disease and meibomian gland dysfunction.

“With TearCare-targeted thermal care, we know that we have a tremendous opportunity to provide a very cost-effective, immediate treatment in office that actually feels good,” he said. “We know from the robust SAHARA data that this treatment, TearCare, is as effective, if not more so effective, on most metrics than chronic immunomodulatory therapy.”

Desai also explained why these positive results reinforce the need for “fair and equitable access” to TearCare (Sight Sciences).

Published by:

Read more about

This post was originally published on this site